

Distinct Geographic Distributions of Hepatitis B Virus Genotypes in Patients With Acute Infection in Japan

Hiroshi Yotsuyanagi,^{1*} Chiaki Okuse,¹ Kiyomi Yasuda,² Etsuro Orito,³ Shuhei Nishiguchi,⁴ Joji Toyoda,⁵ Eiichi Tomita,⁶ Keisuke Hino,⁷ Kiwamu Okita,⁷ Shiro Murashima,⁸ Michio Sata,⁸ Hiromi Hoshino,⁹ Yuzo Miyakawa,¹⁰ Shiro Iino,^{1,2} and
for the Japanese Acute Hepatitis B Group

¹Department of Internal Medicine, Division of Gastroenterology and Hepatology, St. Marianna University School of Medicine, Kawasaki, Japan

²Center for Liver Diseases, Kiyokawa Hospital, Tokyo, Japan

³Department of Clinical Molecular Informative Medicine, Nagoya City University Graduate School of Medicine, Nagoya, Japan

⁴Department of Hepatology, Graduate School of Medicine, Osaka City University, Osaka, Japan

⁵Department of Hepatology, Sapporo Kosei General Hospital, Sapporo, Japan

⁶Department of Gastroenterology, Gifu Municipal Hospital, Gifu, Japan

⁷Department of Gastroenterology and Hepatology, Yamaguchi University School of Medicine, Ube, Japan

⁸Second Department of Internal Medicine, Kurume University School of Medicine, Kurume, Japan

⁹Hepatitis Research Institute, Tokorozawa, Japan

¹⁰Miyakawa Memorial Research Foundation, Tokyo, Japan

Genotypes of hepatitis B virus (HBV) were determined in 145 patients with acute hepatitis B from various districts in Japan to establish their geographic distribution and evaluating the influence on the clinical illness and outcome. Genotypes were A in 27 (19%) patients, B in 8 (5%), C in 109 (75%) and mixed with B and C in the remaining one (1%). Genotype A was more frequent in metropolitan than the other areas (21/69 (30%) vs. 6/76 (8%), $P < 0.001$). On phylogenetic analysis, seven of the nine (78%) HBV/A isolates selected at random clustered with those from Europe and the United States, while the remaining two with those of subgroup A' prevalent in Asia and Africa. Maximum ALT levels were lower (2069 ± 1075 vs. 2889 ± 1867 IU/L, $P = 0.03$) and baseline HBV DNA titers were higher (5.90 ± 1.45 vs. 5.13 ± 1.36 log genome equivalents (LGE)/ml, $P = 0.002$) in patients infected with genotype A than C. Hepatitis B surface antigen persisted longer in patients infected with genotype A than C (1.95 ± 1.09 vs. 1.28 ± 1.42 months, $P = 0.02$). HBV infection became chronic in one (4%) patient with genotype A and one (1%) with genotype C infection. Fulminant hepatic failure developed in none of the patients with genotype A, one (13%) with genotype B and five (5%) with genotype C. The point mutation in the precore region (A1896) or the double mutations in the basic core promoter (BCP) region

(T1762/A1764) were detected in none of the patients with genotype A, two (25%) with genotype B and 27 (26%) with genotype C. In conclusion, genotype A is frequent in patients with acute hepatitis B in metropolitan areas of Japan, probably reflecting particular transmission routes, and associated with longer and milder clinical course than genotype C. *J. Med. Virol.* 77:39–46, 2005. © 2005 Wiley-Liss, Inc.

KEY WORDS: acute hepatitis; genotypes; epidemiology; hepatitis B virus; hepatitis B e antigen; sexuality; Japan

Grant sponsor: Japanese Ministry of Health, Labor and Welfare.

Dr. Hiroshi Yotsuyanagi's present address is Department of Infectious Diseases, Faculty of Medicine, University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo 113-8655, Japan.

*Correspondence to: Dr. Hiroshi Yotsuyanagi, Department of Internal Medicine, Division of Gastroenterology and Hepatology, St. Marianna University School of Medicine, 2-16-1, Sugao, Miyamae-ku, Kawasaki, 216-8511, Japan.
E-mail: hyotsu@marianna-u.ac.jp

Accepted 17 May 2005

DOI 10.1002/jmv.20411

Published online in Wiley InterScience
(www.interscience.wiley.com)

INTRODUCTION

The clinical outcome in patients with acute hepatitis B varies widely. Although hepatitis is self-limited in most patients, the clinical features range from asymptomatic to fulminant hepatic failure, while some patients become carriers of hepatitis B virus (HBV) [Chan HL and Lok, 1999; Chan HLY, 1999]. Factors that determine the clinical outcome remain unknown.

Viral nucleotide (nt) mutations have been shown to influence the clinical outcome of acute hepatitis B. Mutations in the precore region (A1896) and the basic core promoter (BCP) region (T1762/A1764) are common in patients with fulminant hepatic failure [Carman et al., 1991; Kosaka et al., 1991; Liang et al., 1991; Omata et al., 1991; Hawkins et al., 1994; Sato et al., 1995; Baumert et al., 1996; Chu et al., 1996]. Viral factors other than these mutations may influence the clinical outcome of acute hepatitis B.

Eight genotypes of HBV have been identified by sequence divergence greater than 8% in the entire genome, and they are designated by capital alphabet letters from A to H [Okamoto et al., 1988; Norder et al., 1994; Stuyver et al., 2000; Arauz-Ruiz et al., 2002]. Furthermore, recombinant HBV strains consisting of two different genotypes have been reported [Bollyky et al., 1996; Morozov et al., 2000]. Genotype distribution is different in different countries and even in distinct areas of the same country [Orito et al., 2001a; Kao, 2002; Kato et al., 2002; Miyakawa and Mizokami, 2003]. Therefore, surveys on genotype distribution may be helpful in identifying transmission routes and evaluating clinical relevance.

It has been shown that the clinical outcome of chronic hepatitis B is influenced by HBV genotypes. In Asian patients with chronic hepatitis B, genotype C is associated with later seroconversion of hepatitis B e antigen (HBeAg) and more severe liver damage than genotype B [Kao et al., 2000; Orito et al., 2001b; Chu et al., 2002; Ding et al., 2002; Sugauchi et al., 2002a]. Likewise, a study from India has shown that genotype D is associated with more severe liver disease than genotype A [Thakur et al., 2002]. Genotype A is peculiar in that A1896 in the precore region occurs infrequently, because it causes instability of the stem-loop structures of the pregenome encapsidation signal [Li et al., 1993; Lok et al., 1994]. These reports suggest that HBV genotypes also influence the clinical characteristics of acute hepatitis. Recent studies on small numbers of patients with acute hepatitis B suggest that the clinical course may differ among infections with distinct HBV genotypes [Mayerat et al., 1999; Kobayashi et al., 2002; Ogawa et al., 2002]. However, the association between viral genotype and severity of liver disease remains uncertain in acute HBV infection.

To evaluate the effect of HBV genotypes on the clinical characteristics of acute hepatitis B, a multi-center study on 145 patients was conducted in Japan.

MATERIALS AND METHODS

Patients

During 1992 through 2001, serum samples were collected from 147 patients diagnosed with acute hepatitis B in our institutions. Only patients from whom sera at the onset of hepatitis were stored were included in this study. Sixty-nine (47%) patients lived in metropolitan areas (Kawasaki, Tokyo and Tokorozawa), while the others in Kurume, Ube, Osaka, Gifu, Nagoya and Sapporo. Criteria for the diagnosis of acute hepatitis B were: (1) Acute onset of liver injury without a history of liver dysfunction and detection of hepatitis B surface antigen (HBsAg) in serum; and (2) IgM antibody to HBV core (anti-HBc) in high titer. Co-infection with hepatitis A virus or hepatitis C virus was excluded by serological tests.

Among the 147 patients, acute hepatitis B in six (4%) was complicated by hepatic encephalopathy and prolonged prothrombin time for the diagnosis of fulminant hepatic failure. Other two (1%) patients remained positive for HBsAg for longer than 6 months, and they were considered to have acquired chronic infection.

Sera from the 147 patients with acute hepatitis B were examined virologically, and the results were correlated with clinical and demographic characteristics. Informed consent was obtained from each patient for the purpose of this study. The study protocol conforms to the ethical guidelines of the 1975 Declaration of Helsinki and approved by the Ethics Committees of our institutions.

Determination of HBV DNA

Levels of HBV DNA were determined using transcription-mediated amplification (TMA) and hybridization-protection assay (Chugai Diagnostics Science Co., Ltd., Tokyo, Japan) after the protocol as reported [Kamisango et al., 1999]. The range of detection by TMA was from 3.7 log genome equivalents (LGE)/ml ($10^{3.7}$ copies/ml corresponding to 5,000 copies/ml) to 8.7 LGE/ml ($10^{8.7}$ copies/ml). In 16 of 86 studied sera, levels of HBV DNA were under 3.7 LGE/ml and categorized in 3.7 LGE/ml.

Genotyping HBV

HBV genotypes in most samples were determined with commercial enzyme immunoassay kits (HBV Genotype EIA, Institute of Immunology Co. Ltd., Tokyo, Japan) involving monoclonal antibodies to genotype-specific epitopes in the preS2-region, as reported previously [Usuda et al., 1999, 2000; Kato et al., 2001]. Genotypes in 18 (12%) samples were determined by genotype-specific probe assay (Smitest HBV Genotyping Kit, Genome Science, Fukushima, Japan). In brief, DNA extracted from serum was amplified by the polymerase chain reaction (PCR) with three sense primers (s1: 5'-ACC AAC CCT CTG GGA TTC TTT CC-3', s2: 5'-ACC AAT CCT CTG GGA TTC TTC CC-3' and s3: 5'-AGC AAT CCT CTA GGA TTC CTT CC-3' [nt 2902-2924]) and an antisense primer (as1: 5'-GAG CCT GAG GGC TCC ACC C-3' [nt 3091-3073]) biotinylated at the 5'-end;

they were deduced from conserved sequences in the preS1 region of HBV. The biotin-labeled and amplified HBV DNA was denatured in an alkaline solution, and tested for hybridization to probes specific for one or other of the seven genotypes (A–G) immobilized on wells of a 96-well microplate. Thereafter, hybridization was detected by staining with the streptavidine-horseradish peroxidase (HRP) conjugate [Kato et al., 2003].

Subtypes of genotype B, in terms of Ba with the recombination with genotype C and Bj without it were determined by direct sequencing of precore and core regions by the method reported previously [Sugauchi et al., 2002b].

Amplifying and Sequencing HBV DNA of Genotype A Isolates

A subgroup of genotype A is reported with the designation of A' from South Africa, Philippines, Malawi, and Belgium [Bowyer et al., 1997; Kramvis et al., 2002; Sugauchi et al., 2004]. Randomly selected HBV/A samples were classified into genotype A and subtype A' by sequencing the S region. For amplification and sequencing, the entire S region was divided into two fragments, spanning nt 3130–478 and nt 378–878, respectively, and they were amplified by two-stage PCR. The outer primers for amplification of the 1st fragment were: 5'-ACC AAT CGG CAG TCA GGA AG-3' (sense: nt 3121–3140) and 5'-CTG GAA TTA GAG GAC AAA CG-3' (antisense: nt 488–469) and the inner primers were: 5'-CAG TCA GGA AGG CAG CCT ACT-3' (sense: nt 3130–3150) and 5'-AGG ACA AAC GGG CAA CAT AC-3' (antisense: nt 478–459). The outer primers for amplification of the 2nd fragment were: 5'-TGT CCT GGT TAT CGC TGG AT-3' (sense: nt 359–378) and 5'-CAA CGT ACC CCA ACT TCC AA-3' (antisense: nt 909–890) and the inner primers were: 5'-TGT GTC TGC GGC GTT TTA TC-3' (sense: nt 378–397) and 5'-ATG AAG TTT AGG GAA TAA CC-3' (antisense: nt 878–859).

The first stage of amplification was carried out in a thermal cycler for 40 cycles (94°C, 1 min; 55°C, 1 min; 72°C, 1 min) in 100 µl of the reaction mixture containing 200 µM dNTPs, 1.0 µM each of primers and 1 × PCR buffer (50 mM KCl, 10 mM Tris-HCl (pH 8.3), 1.5 mM MgCl₂ and 0.001% (wt/vol) gelatin) and 2 U of Ampli-Taq polymerase (Perkin Elmer Cetus Corp., Connecticut). PCR products (2 µl) were subjected to the second stage of amplification under the same conditions as the first stage. Standard precautions to avoid contamination were exercised during PCR, with a negative control serum included in each run.

Amplification products were purified on Wizard PCR preps DNA purification resin (Promega, Wisconsin), and sequenced bidirectionally with the Dye Terminator Cycle Sequencing Ready Reaction Kit (PE Applied Biosystems, California) using the PCR primers. Sequencing was performed in an automated DNA sequencer (ABI 377: PE Applied Biosystems).

The nucleotide sequences of HBV/A isolates from patients were compared with those of 25 reference HBV/

A strains including subtype A' retrieved from the DDBJ/EMBL/GenBank database, as well as representatives of the other six major genotypes (B–G). Phylogenetic trees were constructed with the mega program version 2.1 using the Kimura two-parameter matrix and the neighbor-joining method [Sugita et al., 1991]. To confirm the reliability of phylogenetic tree analysis, bootstrap resampling, and reconstruction were carried out 500 times.

Detection of Point Mutations in the Precore and BCP Regions of HBV

Mutation in the precore region for A1896 was detected by enzyme-linked minisequence assay (Smitest HBV Pre-C ELMA, Roche Diagnostics, Tokyo, Japan) and mutations in the BCP region for T1762/A1764 were detected by enzyme-linked specific probe assay (Smitest HBV Core Promoter Mutation Detection Kit; Genome Science Laboratory, Tokyo, Japan) according to the manufacturer's instructions, after the principles described previously [Orito et al., 2001b]. The results were recorded as "the wild-type" and "the mutant-type" expressed dominantly by HBV isolates.

Statistical Analysis

Data were analyzed by chi-square test or Fisher's exact test for categorical data and Student's *t*-test or Mann-Whitney *U*-test for continuous variables. *P*-values less than 0.05 were regarded as statistically significant. Logistic regression (backward logistic regression) was used in the multivariate analysis to evaluate the factors associated with differences between genotypes A and C.

RESULTS

Distribution of HBV Genotypes

HBV genotypes were determined in 145 of the 147 (99%) patients with acute hepatitis B; they were untypeable in the remaining two patients (Table I). Genotype A was detected in 27 (19%) patients, B in 8 (5%), C in 109 (75%), and mixed genotypes with B and C in the remaining one (1%). In the 69 patients with acute hepatitis B from metropolitan areas (Tokyo, Kawasaki, and Tokorozawa), genotype A was found in 21 (30%), B in 5 (7%), and C in 43 (63%). In the 76 patients from the other areas in the mainland, by contrast, genotype A occurred in 6 (8%), B in 3 (4%), C in 66 (87%), and mixed genotypes with B and C in one (1%). Thus, genotype A was significantly more frequent in patients with acute hepatitis B from the metropolitan than the other areas (30% vs. 8%, *P* < 0.001).

Demographic and Clinical Differences Among Patients Infected With HBV of Distinct Genotypes

Clinical and demographic backgrounds in patients with acute hepatitis B who were infected with HBV of

TABLE I. Demographic and Clinical Differences Among Patients With Acute Hepatitis Who Were Infected With HBV of Distinct Genotypes

Features	Genotypes of HBV				Differences (A vs. C)	
	A (n = 27)	B (n = 8)	C (n = 109)	B/C (n = 1)	Univariate (<i>P</i> -value)	Multivariate logistic regression (<i>P</i> -value)
Areas					<0.001	0.03
Metropolitan (n = 69)	21 (30%)	5 (7%)	43 (63%)	0		
Others (n = 76)	6 (8%)	3 (4%)	66 (87%)	1 (1%)		
Age (years)	29.3 ± 8.0	35.7 ± 10.1	36.6 ± 13.6	51	0.016	0.152
Male	25 (93%)	7 (88%)	69 (57%)	1 (100%)	0.003	0.018
Transmission routes						
Heterosexual	15 (56%)	3 (37%)	52 (48%)	0	0.197	
Homosexual	5 (19%)	1 (13%)	2 (2%)	0	<0.001	0.133
IV drugs	0	0	8 (7%)	0	0.280	
Unknown	7 (25%)	4 (50%)	47 (43%)	1 (100%)	0.102	
Fulminant hepatic failure	0	1 (13%)	5 (5%)	0	0.582	
ALT (IU/L) ^a	2069 ± 1075	2952 ± 1106	2889 ± 1867	646	0.030	0.084
Bilirubin (mg/dl) ^a	10.7 ± 14.1	10.3 ± 4.9	7.8 ± 6.7	4.8	0.533	
ALP (IU/L) ^a	476 ± 161	501 ± 94	432 ± 116	No data	0.542	
HBeAg	24/26 (92%)	4/8 (50%)	57/93 (61%)	1/1 (100%)	0.357	
Precore and BCP mutations						
Precore (1896A)	0/27	1/8 (13%)	20/102 (20%)	No data	0.250	
BCP (1762T/1764A)	0/27	1/6 (17%)	14/75 (19%)	No data	0.357	
Precore or BCP	0/27	2/8 (25%)	27/102 (26%)	No data	0.096	

^aMaximum data are shown for alanine aminotransferase (ALT), bilirubin and alkaline phosphatase (ALP).

different genotypes are compared in Table I. Patients with genotype A were younger than those with genotype C (29.3 ± 8.0 vs. 36.6 ± 13.6 years, *P* = 0.016). The proportion of male patients was higher in genotype A than C infection (93% vs. 57%, *P* = 0.003). The main route of transmission identified in the patients with acute hepatitis B was extramarital heterosexual contacts. Homosexual activity was more frequent in patients with genotype A than C (5/27 (19%) vs. 2/109 (1.8%), *P* < 0.001).

The maximum ALT levels were lower in patients with genotype A than B or C infection (2069 ± 1075, 2952 ± 1106 and 2889 ± 1867 IU/L, respectively; A vs. B, *P* = 0.02; A vs. C, *P* = 0.03). The maximum bilirubin and alkaline phosphatase levels were no different among patients infected with HBV of different genotypes. Fulminant hepatic failure developed in one (13%) patient with genotype B and five (5%) with genotype C; no patients with genotype A came down with it. Evolution into chronic infection occurred in two patients (one with genotype A and one with genotype C). The remaining 137 (96%) patients ran a non-fulminant and self-limited disease.

HBeAg was found in 24 of the 26 (92%) patients with genotype A, 4 of the 8 (50%) with genotype B and 57 of the 93 (61%) with genotype C; it was no different between genotype A than genotype C infection (*P* = 0.357). Of the six patients with fulminant hepatic failure, only one (17%) had HBeAg.

With logistic multivariate regression analysis, the variables for differences between genotypes A and C were sex (odds ratio (OR), 6.45; 95% confidence interval

(CI), 1.378–30.213; *P* = 0.0018) and area (OR, 0.25; 95% CI, 0.076–0.830; *P* = 0.0024).

Routes of transmission were compared between genotypes A and C in patients with acute hepatitis B from metropolitan areas. Although the mean age was no different, frequently the proportion of male patients was higher in genotype A than C infection (20/21 (95%) vs. 28/43 (65%), *P* = 0.012). Homosexual patients had more frequently genotype A than C infection (5/21 (24%) vs. 1/44 (2%), *P* = 0.012). Additionally heterosexuals with multiple unspecified partners had in genotype A more frequently than C infection (7/12 (58%) vs. 6/26 (23%), *P* = 0.035, respectively). However, with logistic multivariate regression analysis, none of these variables differed between genotype A and C infections.

Figure 1 compares serum HBV DNA levels on admission among patients infected with different genotypes. HBV DNA levels were higher in patients with genotype A than C (5.90 ± 1.45 vs. 5.13 ± 1.36 LGE/ml, *P* = 0.002).

Among the 145 patients whose HBV genotypes could be determined, 54 (A: 15, B: 4, and C: 35) were followed for HBsAg in serum every 2–4 weeks until it disappeared. The time between the first and last detection of HBsAg was defined as the duration of HBsAg, and compared between patients infected with HBV of genotypes A and C (Fig. 2a). The duration of HBsAg was longer in patients with genotype A than C infection (1.95 ± 1.09 (n = 15) vs. 1.28 ± 1.42 months (n = 35), *P* = 0.02). When patients with fulminant hepatic failure were excluded, the mean duration of HBsAg in patients with genotype C became longer, but it was still shorter




Fig. 1. HBV-DNA levels in patients with acute hepatitis B with genotypes A, B, or C at the presentation. Box plots are given with horizontal lines for the medians, upper and lower edges indicating the 25th and 75th centiles, respectively, and bars represent the extremes without including outliers. Shaded areas are outside the range of detection by the TMA method.

than that in those with genotype A (1.95 ± 1.09 (n = 15) vs. 1.41 ± 1.42 (n = 31) months, $P = 0.03$).

Subtypes of Genotypes A and B

Among the 27 HBV/A isolates, 9 were selected at random and the entire S region was amplified and sequenced for them. Seven of them were classified into genotype A and the remaining 2 into subgroup A'. The sequence divergence within the seven genotype A isolates ranged from 0.12% to 2.01% in pair-wise comparison, while that between two subgroup A' and seven genotype A isolates spanned from 5.70% to 6.53%.

A phylogenetic tree was constructed on the entire S-gene sequences from these nine sequences along with those from 31 HBV isolates retrieved from the database (Fig. 3). The seven (78%) HBV isolates classified into genotype A clustered with reported HBV/A isolates, while the remaining two isolates classified into subgroup A' (cases 3 and 4) joined the branch of subgroup A'.

Six of the eight HBV/B isolates were available for analysis of subtypes. Two (both from the metropolitan area) were classified as Ba and the remaining four, in-




Fig. 2. The duration of HBsAg in patients with acute hepatitis B with genotypes A or C. The results are shown for (a) all patients, and (b) patients with the wild-type sequences both in precore and BCP regions of HBV.

cluding two from Tokyo and two from the other areas, as B_j. One of the four patients infected with subtype B_j developed fulminant hepatic failure, while the remaining three with subtype B_j as well as the two with subtype B_a ran a non-fulminant course.

Point Mutations in the Precore and Basic Core Promoter Regions of HBV

All the 27 HBV isolates of genotype A in which mutations were sought had the wild-type sequences both in the precore and BCP regions. In contrast, of the 102 genotype C isolates whose precore and BCP sequences were examined, 27 (26%) had mutations in the precore or BCP regions ($P = 0.096$). Furthermore, of the four genotype C isolates from patients with fulminant hepatic failure whose genetic mutations could be determined, three had mutations in the BCP region (T1762/A1764) and two had a mutation in the precore region (A1896). Only one isolate had the wild-type sequences both in the precore and BCP regions. Of

DISCUSSION




Fig. 3. A phylogenetic tree constructed on HBV DNA sequences spanning the major S-gene of all known HBV genomes, including the nine of genotype A. The horizontal bar indicates the number of nucleotide substitutions per site. Accession numbers are shown for the isolates, which have been deposited in the DDBJ/EMBL/GenBank databases. HBV sequences in cases 1–9 were determined in the present study. The HBV/A sequences from cases 1, 2, and 5–9 clustered with the European-American genotype A, while those from cases 3 and 4 clustered with genotype A' that is the African subgroup of genotype A.

the eight genotype B isolates, two (25%) had mutations in the precore or BCP region (Table I).

To examine further differences between genotype A and C infections, patients infected with HBV strains with the wild-type sequences both in precore and BCP regions were compared. The maximum ALT levels were still lower in patients with genotype A than C infection (2069 ± 1075 and 2594 ± 1015 IU/L, respectively, $P = 0.02$), but the maximum bilirubin and alkaline phosphatase levels were no different amongst patients infected with HBV of distinct genotypes. There were no differences in the duration of serum HBsAg between patients with genotype A and C infections (1.95 ± 1.09 vs. 1.58 ± 1.24 months, $P = 0.35$) (Fig. 2b).

The salient finding in this study is that infection with HBV genotype A is frequent in patients with acute hepatitis in Japan, lending support to previous studies [Kobayashi et al., 2002; Ogawa et al., 2002]. Substantial portion of patients with acute hepatitis were infected with genotype A, which is detected rarely among patients with chronic hepatitis in Japan [Orito et al., 2001a; Kobayashi et al., 2002]. Genotype A prevails in North-Western Europe, United States, Central Africa, and India [Kao, 2002; Miyakawa and Mizokami, 2003]. This genotype may be prevalent in countries elsewhere, since the distribution of HBV genotypes has not been examined in many districts of the world. Phylogenetic analysis has shown that seven (78%) HBV/A strains of the nine patients examined with acute hepatitis B were of the European-American type. Although the HBV/A sequences from four, (cases 1, 2, 5, and 7) clustered with those reported previously, those from three (cases 6, 8, and 9) were separated genetically (Fig. 3), which suggests their distinct geographic origin.

Notably, the genotype distribution differed between patients with acute hepatitis B from metropolitan areas and the others including many large cities. As genotype A is seen rarely in patients with chronic hepatitis [Orito et al., 2001a; Kobayashi et al., 2002], it is suspected that genotype A in metropolitan areas has a distinct geographic origin. Many patients with genotype A infection in these areas had a history of extramarital sexual contacts with plural unspecified partners. Such sexual behavior may increase the risk of infection with genotype A. In support of this view, most homosexual people in Tokyo who have human immunodeficiency virus type I are coinfecting with HBV genotype A [Koibuchi et al., 2001]. Taken together, homosexual activity would increase the risk of genotype A infection in metropolitan areas. Further molecular analysis on HBV isolates from transmitters and recipients will verify this hypothesis. With respect to genotype B, both Ba, and B_j subtypes [Sugauchi et al., 2002b] were detected. Although the number of studied patients was small, patients with subtype Ba were found in the Tokyo metropolitan area exclusively. Whether subtype Ba intrinsic to the metropolitan area has a peculiar geographic origin is currently unknown and awaits further analyses.

Another point made in this study is that HBV genotypes influence clinical features and the outcome of acute hepatitis B. It has been shown that the proportion of patients who develop chronic HBV infection is close to 10% in European and American countries [Sherlock S, 1997] but rare in Japan [Kobayashi et al., 2002]. Recent studies suggest that chances for evolution into chronicity may differ among patients acutely infected with HBV of distinct genotypes [Mayerat et al., 1999; Ogawa et al., 2002]. Our study has shown that patients with genotype A had higher HBV DNA and lower ALT levels, as well as a longer duration of HBsAg in serum. Development of chronic hepatitis was seen in one of the 27 (4%) patients with genotype A as against one of the 109 (1%)

with genotype C infection. Although the number of patients studied was not large enough for statistical evaluation, the transition to chronic infection may be more frequent in infection with genotype A than the other genotypes, insofar as higher viral loads can predict chronic infection [Fong et al., 1994]. Further studies on more patients are required to evaluate whether or not viral persistence occurs more often after HBV infection with genotype A than the other genotypes.

Patients with fulminant hepatic failure in the present study were infected with either genotypes B or C; no patient with genotype A developed hepatic failure. As mutations at nt 1896 in the precore and nt 1762/1764 in the BCP regions, which are found frequently in patients with fulminant hepatic failure [Carman et al., 1991; Kosaka et al., 1991; Liang et al., 1991; Omata et al., 1991; Hawkins et al., 1994; Sato et al., 1995; Baumert et al., 1996; Chu et al., 1996], were not detected in patients with genotype A, low frequency of fulminant hepatic failure associated with genotype A infection may be attributed to the lack of these mutations. The high frequency of HBeAg in genotype A infection may also be related to low frequency of fulminant hepatic failure. However, interpretation on this data should be made carefully, because the number of patients studied was small. Further research is necessary to determine if the genotype itself affects the clinical course of acute hepatitis B.

In summary, (1) infection with HBV genotype A is common in patients with acute hepatitis in Japan; (2) patients with genotype A are more frequent in metropolitan areas and may be associated with particular sexual behavior; (3) patients with genotype A have a milder but longer course of infection, which may lead to increased risk of progression to chronic disease.

ACKNOWLEDGMENTS

We thank Ms. Kuniko Shibahara for her excellent technical assistance.

REFERENCES

- Arauz-Ruiz P, Norder H, Robertson BH, Magnius LO. 2002. Genotype H: A new Amerindian genotype of hepatitis B virus revealed in Central America. *J Gen Virol* 83:2059–2073.
- Baumert TF, Rogers SA, Hasegawa K, Liang TJ. 1996. Two core promoter mutations identified in a hepatitis B virus strain associated with fulminant hepatitis result in enhanced viral replication. *J Clin Invest* 98:2268–2276.
- Bollyky PL, Rambaut A, Harvey PH, Holmes EC. 1996. Recombination between sequences of hepatitis B virus from different genotypes. *J Mol Evol* 42:97–102.
- Bowyer SM, van Staden L, Kew MC, Sim JG. 1997. A unique segment of the hepatitis B virus group A genotype identified in isolates from South Africa. *J Gen Virol* 78:1719–1729.
- Carman WF, Fagan EA, Hadziyannis S, Karayiannis P, Tassopoulos NC, Williams R, Thomas HC. 1991. Association of a precore genomic variant of hepatitis B virus with fulminant hepatitis. *Hepatology* 14:219–222.
- Chan HL GM, Lok ASF. 1999. Hepatitis B. In: Schiff ER SM, Maddrey WC, editors. *Diseases of the liver*, 8th edn. Philadelphia: Lippincott Williams & Wilkins. 763p.
- Chan HLY LA, editor. 1999. *Hepatitis B in adults*. Philadelphia: W.B. Saunders Company. pp 291–308.
- Chu CM, Yeh CT, Chiu CT, Sheen IS, Liaw YF. 1996. Precore mutant of hepatitis B virus prevails in acute and chronic infections in an area in which hepatitis B is endemic. *J Clin Microbiol* 34:1815–1818.
- Chu CJ, Hussain M, Lok AS. 2002. Hepatitis B virus genotype B is associated with earlier HBeAg seroconversion compared with hepatitis B virus genotype C. *Gastroenterology* 122:1756–1762.
- Ding X, Mizokami M, Ge X, Orito E, Iino S, Ueda R, Nakanishi M. 2002. Different hepatitis B virus genotype distributions among asymptomatic carriers and patients with liver diseases in Nanning, Southern China. *Hepatology* 22:37–44.
- Fong TL, Di Bisceglie AM, Biswas R, Waggoner JG, Wilson L, Claggett J, Hoofnagle JH. 1994. High levels of viral replication during acute hepatitis B infection predict progression to chronicity. *J Med Virol* 43:155–158.
- Hawkins AE, Gilson RJ, Beath SV, Boxall EH, Kelly DA, Tedder RS, Weller IV. 1994. Novel application of a point mutation assay: Evidence for transmission of hepatitis B viruses with precore mutations and their detection in infants with fulminant hepatitis B. *J Med Virol* 44:13–21.
- Kamisango K, Kamogawa C, Sumi M, Goto S, Hirao A, Gonzales F, Yasuda K, Iino S. 1999. Quantitative detection of hepatitis B virus by transcription-mediated amplification and hybridization protection assay. *J Clin Microbiol* 37:310–314.
- Kao JH. 2002. Hepatitis B viral genotypes: Clinical relevance and molecular characteristics. *J Gastroenterol Hepatol* 17:643–650.
- Kao JH, Chen PJ, Lai MY, Chen DS. 2000. Hepatitis B genotypes correlate with clinical outcomes in patients with chronic hepatitis B. *Gastroenterology* 118:554–559.
- Kato H, Orito E, Sugauchi F, Ueda R, Gish RG, Usuda S, Miyakawa Y, Mizokami M. 2001. Determination of hepatitis B virus genotype G by polymerase chain reaction with hemi-nested primers. *J Virol Methods* 98:153–159.
- Kato H, Orito E, Gish RG, Sugauchi F, Suzuki S, Ueda R, Miyakawa Y, Mizokami M. 2002. Characteristics of hepatitis B virus isolates of genotype G and their phylogenetic differences from the other six genotypes (A through F). *J Virol* 76:6131–6137.
- Kato H, Orito E, Sugauchi F, Ueda R, Koshizaka T, Yanaka S, Gish RG, Kurbanov F, Ruzibakiev R, Kramvis A, Kew MC, Ahmad N, Khan M, Usuda S, Miyakawa Y, Mizokami M. 2003. Frequent coinfection with hepatitis B virus strains of distinct genotypes detected by hybridization with type-specific probes immobilized on a solid-phase support. *J Virol Methods* 110:29–35.
- Kobayashi M, Arase Y, Ikeda K, Tsubota A, Suzuki Y, Saitoh S, Suzuki F, Akuta N, Someya T, Matsuda M, Sato J, Takagi K, Miyakawa Y, Kumada H. 2002. Viral genotypes and response to interferon in patients with acute prolonged hepatitis B virus infection of adulthood in Japan. *J Med Virol* 68:522–528.
- Koibuchi T, Hitani A, Nakamura T, Nojiri N, Nakajima K, Jyuji T, Iwamoto A. 2001. Predominance of genotype A HBV in an HBV-HIV-1 dually positive population compared with an HIV-1-negative counterpart in Japan. *J Med Virol* 64:435–440.
- Kosaka Y, Takase K, Kojima M, Shimizu M, Inoue K, Yoshida M, Tanaka S, Akahane Y, Okamoto H, Tsuda F, Miyakawa Y, Mayumi M. 1991. Fulminant hepatitis B: Induction by hepatitis B virus mutants defective in the precore region and incapable of encoding e antigen. *Gastroenterology* 100:1087–1094.
- Kramvis A, Weitzmann L, Owiredu WK, Kew MC. 2002. Analysis of the complete genome of subgroup A' hepatitis B virus isolates from South Africa. *J Gen Virol* 83:835–839.
- Li JS, Tong SP, Wen YM, Vitvitski L, Zhang Q, Trepo C. 1993. Hepatitis B virus genotype A rarely circulates as an HBe-minus mutant: Possible contribution of a single nucleotide in the precore region. *J Virol* 67:5402–5410.
- Liang TJ, Hasegawa K, Rimon N, Wands JR, Ben-Porath E. 1991. A hepatitis B virus mutant associated with an epidemic of fulminant hepatitis. *N Engl J Med* 324:1705–1709.
- Lok AS, Akarca U, Greene S. 1994. Mutations in the pre-core region of hepatitis B virus serve to enhance the stability of the secondary structure of the pre-genome encapsidation signal. *Proc Natl Acad Sci USA* 91:4077–4081.
- Mayerat C, Mantegani A, Frei PC. 1999. Does hepatitis B virus (HBV) genotype influence the clinical outcome of HBV infection? *J Viral Hepat* 6:299–304.
- Miyakawa Y, Mizokami M. 2003. Classifying hepatitis B virus genotypes. *Intervirology* 46:329–338.

- Morozov V, Pisareva M, Groudinin M. 2000. Homologous recombination between different genotypes of hepatitis B virus. *Gene* 260: 55-65.
- Norder H, Courouce AM, Magnius LO. 1994. Complete genomes, phylogenetic relatedness, and structural proteins of six strains of the hepatitis B virus, four of which represent two new genotypes. *Virology* 198:489-503.
- Ogawa M, Hasegawa K, Naritomi T, Torii N, Hayashi N. 2002. Clinical features and viral sequences of various genotypes of hepatitis B virus compared among patients with acute hepatitis B. *Hepatol Res* 23:167-177.
- Okamoto H, Tsuda F, Sakugawa H, Sastrosowignjo RI, Imai M, Miyakawa Y, Mayumi M. 1988. Typing hepatitis B virus by homology in nucleotide sequence: Comparison of surface antigen subtypes. *J Gen Virol* 69:2575-2583.
- Omata M, Ehata T, Yokosuka O, Hosoda K, Ohto M. 1991. Mutations in the precore region of hepatitis B virus DNA in patients with fulminant and severe hepatitis. *N Engl J Med* 324:1699-1704.
- Orito E, Ichida T, Sakugawa H, Sata M, Horiike N, Hino K, Okita K, Okanoue T, Iino S, Tanaka E, Suzuki K, Watanabe H, Hige S, Mizokami M. 2001a. Geographic distribution of hepatitis B virus (HBV) genotype in patients with chronic HBV infection in Japan. *Hepatology* 34:590-594.
- Orito E, Mizokami M, Sakugawa H, Michitaka K, Ishikawa K, Ichida T, Okanoue T, Yotsuyanagi H, Iino S. 2001b. A case-control study for clinical and molecular biological differences between hepatitis B viruses of genotypes B and C. Japan HBV Genotype Research Group. *Hepatology* 33:218-223.
- Sato S, Suzuki K, Akahane Y, Akamatsu K, Akiyama K, Yunomura K, Tsuda F, Tanaka T, Okamoto H, Miyakawa Y, et al. 1995. Hepatitis B virus strains with mutations in the core promoter in patients with fulminant hepatitis. *Ann Intern Med* 122:241-248.
- Sherlock S DJ. 1997. Virus hepatitis. In: Sherlock S DJ, editor. *Diseases of the Liver and biliary system*, 10th edn. London: Blackwell Scientific Publications. pp 265-392.
- Stuyver L, De Gendt S, Van Geyt C, Zoulim F, Fried M, Schinazi RF, Rossau R. 2000. A new genotype of hepatitis B virus: Complete genome and phylogenetic relatedness. *J Gen Virol* 81: 67-74.
- Sugauchi F, Chutaputti A, Orito E, Kato H, Suzuki S, Ueda R, Mizokami M. 2002a. Hepatitis B virus genotypes and clinical manifestation among hepatitis B carriers in Thailand. *J Gastroenterol Hepatol* 17:671-676.
- Sugauchi F, Orito E, Ichida T, Kato H, Sakugawa H, Kakumu S, Ishida T, Chutaputti A, Lai CL, Ueda R, Miyakawa Y, Mizokami M. 2002b. Hepatitis B virus of genotype B with or without recombination with genotype C over the precore region plus the core gene. *J Virol* 76:5985-5992.
- Sugauchi F, Kumada H, Acharya SA, Shrestha SM, Gamutan MT, Khan M, Gish RG, Tanaka Y, Kato T, Orito E, Ueda R, Miyakawa Y, Mizokami M. 2004. Epidemiological and sequence differences between two subtypes (Ae and Aa) of hepatitis B virus genotype A. *J Gen Virol* 85:811-820.
- Sugita S, Yoshioka Y, Itamura S, Kanegae Y, Oguchi K, Gojobori T, Nerome K, Oya A. 1991. Molecular evolution of hemagglutinin genes of H1N1 swine and human influenza A viruses. *J Mol Evol* 32:16-23.
- Thakur V, Guptan RC, Kazim SN, Malhotra V, Sarin SK. 2002. Profile, spectrum and significance of HBV genotypes in chronic liver disease patients in the Indian subcontinent. *J Gastroenterol Hepatol* 17:165-170.
- Usuda S, Okamoto H, Iwanari H, Baba K, Tsuda F, Miyakawa Y, Mayumi M. 1999. Serological detection of hepatitis B virus genotypes by ELISA with monoclonal antibodies to type-specific epitopes in the preS2-region product. *J Virol Methods* 80:97-112.
- Usuda S, Okamoto H, Tanaka T, Kidd-Ljunggren K, Holland PV, Miyakawa Y, Mayumi M. 2000. Differentiation of hepatitis B virus genotypes D and E by ELISA using monoclonal antibodies to epitopes on the preS2-region product. *J Virol Methods* 87: 81-89.